Apo/Lipoproteins
Recommend an article on apo/lipoproteins & atherosclerosis for next month's issue.

• Abstract Hepatic proprotein convertases modulate HDL metabolism.
  (Jin W, et al. Cell Metab. 2007 Aug;6(2):129-36.)
• Possible role of high density lipoprotein in the progression of glomerulosclerosis.
  (Mattana J, et al. J Med. 2003;34(1-6):81-6.)
• Low-density lipoprotein cholesterol in high-risk asymptomatic individuals.
  (Rivera JJ, et al. J Cardiometab Syndr. 2007 Winter;2(1):49-52. Review.)
• High-density lipoprotein as a therapeutic target: a systematic review.
  (Singh IM, et al. JAMA. 2007 Aug 15;298(7):786-98. Review.)
• Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus.
  (Singh S, et al. Indian J Med Res. 2007 Jun;125(6):783-7.)
• Lipoprotein (a) and apolipoprotein (a) phenotypes in healthy Macedonian children.
  (Tosheska K, et al. Bratisl Lek Listy. 2007;108(4-5):179-83.)

Biomarkers
Recommend an article on biomarkers & atherosclerosis for next month's issue.

• Osteoprotegerin: A novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients.
  (Avignon A, et al. Diabetes Care. 2007 Aug 21; [Epub ahead of print])
• Lipoprotein-associated phospholipase a(2) : review of its role as a marker and a potential participant in coronary endothelial dysfunction.
  (Lavi S, et al. Mol Diagn Ther. 2007;11(4):219-26.)

Clinical Trials
Recommend an article on clinical trials & atherosclerosis for next month's issue.

Diabetes
Recommend an article on diabetes & atherosclerosis for next month's issue.

• Renal dysfunction is the most important predictor of the extent and severity of coronary artery disease in patients with diabetes mellitus.
  (Abaci A, et al. Coron Artery Dis. 2007 Sep;18(6):463-9.
• Postprandial lipemia: An under-recognized atherogenic factor in patients with diabetes mellitus.
  (Pastromas S, et al. Int J Cardiol. 2007 Aug 7; [Epub ahead of print])
• Dyslipidaemia in diabetic patients: time for a rethink.
  (Shepherd J. Diabetes Obes Metab. 2007 Sep;9(5):609-16.)
• The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy.
  (Thomas JE, et al. J Cardiometab Syndr. 2007 Spring;2(2):108-13. Review.)

Drug Therapy
Recommend an article on drug therapy & atherosclerosis for next month's issue.

• Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study.
  (Mabuchi H, et al. Atherosclerosis. 2007 Aug 4; [Epub ahead of print]
• Present-day uses of niacin: effects on lipid and non-lipid parameters.
  (Sanyal S, et al. Expert Opin Pharmacother. 2007 Aug;8(11):1711-7. Review.)
• Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats.
  (Hazra A, et al. Pharm Res. 2007 Aug 3; [Epub ahead of print])
• Statin treatment in children with familial hypercholesterolemia: the younger, the better.
  (Rodenburg J, et al. Circulation. 2007 Aug 7;116(6):664-8. Epub 2007 Jul 30.)